286 related articles for article (PubMed ID: 29777171)
21. Structural studies of intrinsically disordered MLL-fusion protein AF9 in complex with peptidomimetic inhibitors.
Yang Y; Ahmad E; Premkumar V; Liu A; Ashikur Rahman SM; Nikolovska-Coleska Z
Protein Sci; 2024 Jun; 33(6):e5019. PubMed ID: 38747396
[TBL] [Abstract][Full Text] [Related]
22. DOT1L O-GlcNAcylation promotes its protein stability and MLL-fusion leukemia cell proliferation.
Song T; Zou Q; Yan Y; Lv S; Li N; Zhao X; Ma X; Liu H; Tang B; Sun L
Cell Rep; 2021 Sep; 36(12):109739. PubMed ID: 34551297
[TBL] [Abstract][Full Text] [Related]
23. Learning from mouse models of MLL fusion gene-driven acute leukemia.
Schwaller J
Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194550. PubMed ID: 32320749
[TBL] [Abstract][Full Text] [Related]
24. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
25. Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia.
Cermáková K; Tesina P; Demeulemeester J; El Ashkar S; Méreau H; Schwaller J; Rezáčová P; Veverka V; De Rijck J
Cancer Res; 2014 Sep; 74(18):5139-51. PubMed ID: 25082813
[TBL] [Abstract][Full Text] [Related]
26. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes.
Chang MJ; Wu H; Achille NJ; Reisenauer MR; Chou CW; Zeleznik-Le NJ; Hemenway CS; Zhang W
Cancer Res; 2010 Dec; 70(24):10234-42. PubMed ID: 21159644
[TBL] [Abstract][Full Text] [Related]
27. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.
Thiel AT; Feng Z; Pant DK; Chodosh LA; Hua X
Haematologica; 2013 Jun; 98(6):918-27. PubMed ID: 23349306
[TBL] [Abstract][Full Text] [Related]
28. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
Liu W; Deng L; Song Y; Redell M
PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
[TBL] [Abstract][Full Text] [Related]
29. Disordered epigenetic regulation in MLL-related leukemia.
Zhang Y; Chen A; Yan XM; Huang G
Int J Hematol; 2012 Oct; 96(4):428-37. PubMed ID: 23054645
[TBL] [Abstract][Full Text] [Related]
30. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
[TBL] [Abstract][Full Text] [Related]
31. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.
Monroe SC; Jo SY; Sanders DS; Basrur V; Elenitoba-Johnson KS; Slany RK; Hess JL
Exp Hematol; 2011 Jan; 39(1):77-86.e1-5. PubMed ID: 20854876
[TBL] [Abstract][Full Text] [Related]
32. SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.
Chu Y; Chen Y; Guo H; Li M; Wang B; Shi D; Cheng X; Guan J; Wang X; Xue C; Cheng T; Shi J; Yuan W
Oncogene; 2020 Dec; 39(50):7239-7252. PubMed ID: 33037410
[TBL] [Abstract][Full Text] [Related]
33. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
Chen Y; Ernst P
Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
[TBL] [Abstract][Full Text] [Related]
34. The DPY30 subunit in SET1/MLL complexes regulates the proliferation and differentiation of hematopoietic progenitor cells.
Yang Z; Augustin J; Chang C; Hu J; Shah K; Chang CW; Townes T; Jiang H
Blood; 2014 Sep; 124(13):2025-33. PubMed ID: 25139354
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
36. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
Wu F; Nie S; Yao Y; Huo T; Li X; Wu X; Zhao J; Lin YL; Zhang Y; Mo Q; Song Y
Theranostics; 2021; 11(17):8172-8184. PubMed ID: 34373735
[TBL] [Abstract][Full Text] [Related]
37. Frat2 mediates the oncogenic activation of Rac by MLL fusions.
Walf-Vorderwülbecke V; de Boer J; Horton SJ; van Amerongen R; Proost N; Berns A; Williams O
Blood; 2012 Dec; 120(24):4819-28. PubMed ID: 23074275
[TBL] [Abstract][Full Text] [Related]
38. KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements.
Au YZ; Gu M; De Braekeleer E; Gozdecka M; Aspris D; Tarumoto Y; Cooper J; Yu J; Ong SH; Chen X; Tzelepis K; Huntly BJP; Vassiliou G; Yusa K
Leukemia; 2021 Apr; 35(4):1012-1022. PubMed ID: 32764680
[TBL] [Abstract][Full Text] [Related]
39. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
[TBL] [Abstract][Full Text] [Related]
40. SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation.
Ropa J; Saha N; Hu H; Peterson LF; Talpaz M; Muntean AG
Haematologica; 2020 Sep; 105(9):2273-2285. PubMed ID: 33054052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
